Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting
Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting
read more
Dr. Wang Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting
Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual
read more
Dr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read more
Dr. Anand and Dr. Abbey Receive Senior Honor Awards from the American Society of Retina Specialists (ASRS)
In recognition of their time and contributions to the scientific programs of the organization’s annual meetings, Texas Retina’s Rajiv Anand, MD, and Ashkan M. Abbey, MD, recently earned the Senior Honor Award
read more
New, Larger Wichita Falls Office on the Way!
We’re excited to announce that construction is well underway on a new, larger Texas Retina Wichita Falls office designed to better serve our patients. The new office is located at: 6767 Southwest
read more
Celebrating Kim Russell’s 20 Years of Service to Texas Retina
As we continue to recognize team members who have been a part of the Texas Retina family for 20+ years, this week we are celebrating Kim Russell. She joined our practice in
read more
New Clinical Trials at Texas Retina
Over the past two decades, Texas Retina physicians have participated in more than 100 national clinical trials, offering our patients access to promising new treatments for a variety of retina conditions, including
read more
Dr. Abbey Presented Key Results of DAVIO 2 Clinical Trial for Wet AMD at Retina World Congress
At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu),
read more
Celebrating Rita Vega’s 21+ Years of Service to Texas Retina
We continue to recognize Texas Retina team members who have served our practice for 20 years or more. Today, we honor Rita Vegas, who joined Texas Retina in 2002 and currently serves
read more Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology
At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand
read more